Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endo USA Inc., a Keenova Therapeutics Company
The primary objective of this study is to evaluate the effect of 3 dose levels of pagoclone (0.15 mg, 0.30 mg, and 0.60 mg) versus placebo on intravaginal ejaculation latency time (IELT) male patients with primary premature ejaculation.
Age
18–55
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
A male regularly experiencing premature ejaculation
18 to 55 yrs old
In a Stable relationship with one woman for at least 6 months
Clareo Health | Exploratory Study of Pagoclone in Men With Premature Ejaculation.
